… Effects of candesartan in patients with chronic heart failure and reduced left-ventricular
systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.  …

… left ventricular ejection fraction (LVEF). The anticipated increase in the prevalence of HFrEF,
HFmrEF, and HFpEF indicate an unmet clinical need for effective STR treatment options to …

… disease … heart failure with reduced ejection fraction (HFrEF), established therapies for HFrEF,
such as angiotensin receptor blockers, sacubitril/valsartan, and spironolactone, have failed …

… agents on left ventricular ejection time (LVET) in heart failure with reduced ejection fraction
(HFrEF). … enzyme inhibitor; HR, heart rate; LV, left ventricular; LVEF, left ventricular ejection …

… With Preserved Ejection Fraction) trial tested the efficacy of sacubitril-valsartan in patients
with heart failure with preserved ejection fraction (HFpEF). Existing data on cardiac structure …

… The role of exercise training modality to attenuate left ventricular (LV) remodeling in heart
failure patients with reduced ejection fraction (HFrEF) remains uncertain. The authors …

… Comorbidities may precede or develop after heart failure and usually coexist with heart failure
… heart failure progression. Across the heart failure spectrum left ventricular ejection fraction …

… ventricular (LV) remodeling and recovery of LV function are associated with improved clinical
outcomes in patients with heart failure with reduced ejection fraction… of LV ejection fraction, …

… In this study from the CHAMP-HF (Change the Management of Patients with Heart Failure)
registry, we describe changes in left ventricular ejection fraction over time in routine practice. …

… for heart failure across the entire range of ejection fractions seen in clinical practice. We
assessed the influence of ejection fraction on … 2 inhibitor empagliflozin on heart failure outcomes. …